[1] |
DIEHL AM, DAY C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis[J]. N Engl J Med, 2017, 377(21): 2063-2072. DOI: 10.1056/NEJMra1503519.
|
[2] |
GAO JJ, WANG T, JIANG YY, et al. Metabonomics and traditional Chinese medicine syndrome of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(8): 1880-1882. DOI: 10.3969/j.issn.1001-5256.2020.08.044.
高静静, 汪涛, 蒋元烨, 等. 非酒精性脂肪性肝病代谢组学与中医证候[J]. 临床肝胆病杂志, 2020, 36(8): 1880-1882. DOI: 10.3969/j.issn.1001-5256.2020.08.044.
|
[3] |
ANGELICO F, DEL BEN M, CONTI R, et al. Non-alcoholic fatty liver syndrome: A hepatic consequence of common metabolic diseases[J]. J Gastroenterol Hepatol, 2003, 18(5): 588-594. DOI: 10.1046/j.1440-1746.2003.02958.x.
|
[4] |
YANG CQ, SHU L, WANG S, et al. Dietary patterns modulate the risk of non-alcoholic fatty liver disease in chinese adults[J]. Nutrients, 2015, 7(6): 4778-4791. DOI: 10.3390/nu7064778.
|
[5] |
BARSHOP NJ, SIRLIN CB, SCHWIMMER JB, et al. Review article: Epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2008, 28(1): 13-24. DOI: 10.1111/j.1365-2036.2008.03703.x.
|
[6] |
MARDINOGLU A, WU H, BJORNSON E, et al. An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans[J]. Cell Metab, 2018, 27(3): 559-571. e5. DOI: 10.1016/j.cmet.2018.01.005.
|
[7] |
JIMBA S, NAKAGAMI T, TAKAHASHI M, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults[J]. Diabet Med, 2005, 22(9): 1141-1145. DOI: 10.1111/j.1464-5491.2005.01582.x.
|
[8] |
FRIIS-LIBY I, ALDENBORG F, JERLSTAD P, et al. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease[J]. Scand J Gastroenterol, 2004, 39(9): 864-869. DOI: 10.1080/00365520410006431.
|
[9] |
HUANG W, KONG D. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD[J]. Biomed Pharmacother, 2021, 135: 111235. DOI: 10.1016/j.biopha.2021.111235.
|
[10] |
MA X, GU HT, ZHAO Y, et al. Serum metabolomics study on nonalcoholic fatty liver disease with liver damage of different syndromes[J]. China J Tradit Chin Med Pharma, 2017, 32(3): 1246-1250. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201703103.htm
马欣, 顾宏图, 赵瑜, 等. 不同证候的非酒精性脂肪肝合并肝损伤患者的血清代谢组学分析[J]. 中华中医药杂志, 2017, 32(3): 1246-1250. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201703103.htm
|
[11] |
LIN L, YAN H, CHEN J, et al. Application of metabolomics in viral pneumonia treatment with traditional Chinese medicine[J]. Chin Med, 2019, 14: 8. DOI: 10.1186/s13020-019-0229-x.
|
[12] |
Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Guidelines for Management of non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2010, 26(2): 120-124. http://lcgdbzz.org/cn/article/doi/1001-5256%20(2010)%2002-0120-05
中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 临床肝胆病杂志, 2010, 26(2): 120-124. http://lcgdbzz.org/cn/article/doi/1001-5256%20(2010)%2002-0120-05
|
[13] |
NASCIMBENI F, PAIS R, BELLENTANI S, et al. From NAFLD in clinical practice to answers from guidelines[J]. J Hepatol, 2013, 59(4): 859-871. DOI: 10.1016/j.jhep.2013.05.044.
|
[14] |
ZHANG HJ, HE J, PAN LL, et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: A randomized clinical trial[J]. JAMA Intern Med, 2016, 176(8): 1074-1082. DOI: 10.1001/jamainternmed.2016.3202.
|
[15] |
VUPPALANCHI R, CHALASANI N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management[J]. Hepatology, 2009, 49(1): 306-317. DOI: 10.1002/hep.22603.
|
[16] |
SUN GJ, JIANG AL, LI YB, et al. Progress in the research of metabonomics in disease diagnosis and Chinese medicine treatment [J]. Chin J Integr Trad West Med, 2021, 41(1): 122-125. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ202101030.htm
孙桂江, 姜埃利, 李遇伯, 等. 代谢组学在疾病诊断及中药治疗的研究进展[J]. 中国中西医结合杂志, 2021, 41(1): 122-125. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ202101030.htm
|
[17] |
TIAN G, LI C, ZHAI YY, et al. Effect of Pudilan Xiaoyan Oral Liquid on energy metabolism in mice with acute pneumonia induced by LPS based on serum tar-geted metabolomics[J]. J Nangjing Univ Tradit Chin Med, 2021, 37(1): 120-125. DOI: 10.14148/j.issn.1672-0482.2021.0120.
田刚, 李超, 翟园园, 等. 基于血清靶向代谢组学研究蒲地蓝消炎口服液对脂多糖诱导的急性肺炎小鼠能量代谢的影响[J]. 南京中医药大学学报, 2021, 37(1): 120-125. DOI: 10.14148/j.issn.1672-0482.2021.0120.
|
[18] |
MA R, XIE Q, WANG J, et al. Metabolomics study on effects of compatibility of alcohol extracts of Magnolia officinalis and Polygala tenuifolia on urine metabolites in rats[J]. Chin Pharmacol Bull, 2019, 35(6): 870-877. DOI: 10.3969/j.issn.1001-1978.2019.06.026.
马荣, 谢倩, 王建, 等. 基于代谢组学研究厚朴远志配伍醇提物对尿液代谢物的影响[J]. 中国药理学通报, 2019, 35(6): 870-877. DOI: 10.3969/j.issn.1001-1978.2019.06.026.
|
[19] |
WANG X, WANG X, XIE G, et al. Urinary metabolite variation is associated with pathological progression of the post-hepatitis B cirrhosis patients[J]. J Proteome Res, 2012, 11(7): 3838-3847. DOI: 10.1021/pr300337s.
|
[20] |
YU Y. The toxic effect of high dose phenylalanine on mice liver[D]. Changchun: Jilin University, 2018.
于杨. 高苯丙氨酸对小鼠肝脏的毒性作用[D]. 长春: 吉林大学, 2018.
|
[21] |
SUN YX. Explore the protective mechanism of metformin on bisphenol A-induced liver injury in rats based on metabolomics[D]. Zhengzhou: Zhengzhou University, 2020.
孙亚新. 基于代谢组学技术的二甲双脈对双酚A诱导大鼠肝损伤的保护作用机制研究[D]. 郑州: 郑州大学, 2020.
|
[22] |
WANG W, YANG J, QI W, et al. Lipidomic profiling of high-fat diet-induced obesity in mice: Importance of cytochrome P450-derived fatty acid epoxides[J]. Obesity (Silver Spring), 2017, 25(1): 132-140. DOI: 10.1002/oby.21692.
|
[23] |
WATERS PJ, PARNIAK M, AKERMAN BR, et al. Characterization of phenylketonuria missense substitutions, distant from the phenylalanine hydroxylase active site, illustrates a paradigm for mechanism and potential modulation of phenotype[J]. Mol Genet Metab, 2000, 69(2): 101-110. DOI: 10.1006/mgme.2000.2965.
|